Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^☆

TY - JOUR

T1 - Lung and thymic carcinoids

T2 - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

AU - ESMO Guidelines Committee

AU - Baudin, E.

AU - Caplin, M.

AU - Garcia-Carbonero, R.

AU - Fazio, N.

AU - Ferolla, P.

AU - Filosso, P. L.

AU - Frilling, A.

AU - de Herder, W. W.

AU - Hörsch, D.

AU - Knigge, U.

AU - Korse, C. M.

AU - Lim, E.

AU - Lombard-Bohas, C.

AU - Pavel, M.

AU - Scoazec, J. Y.

AU - Sundin, A.

AU - Berruti, A.

N1 - Funding Information: No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. EB has received honoraria from Novartis, Ipsen and Pfizer, research grants from Novartis and he is a member of Ipsen and Novartis speaker's bureau; MC has received research funding and speaker/advisory board honoraria from Ipsen, Novartis, Lexicon and AAA-Pharma; RGC has reported being an advisory board member for Novartis, Ipsen, AAA-Pharma and Pfizer and has received research grants from Pfizer; NF has received honoraria from Novartis, Ipsen, Pfizer, AAA-Pharma, Merck Sharp & Dohme and Merck Serono and research grants from Novartis and Merck Serono; PF has reported advisory board for Novartis, Ipsen, Merck Serono, Pfizer, Lexicon and Italfarmaco and has participated at steering committee for Novartis, Ipsen and Merck Serono; AF is a member of speaker's bureau and has received honoraria from Ipsen, Novartis and Sirtex and has received research grants from Novartis; WWdH has received research grants from Ipsen; DH has received honoraria from Novartis, Ipsen, Pfizer and ROTOP Pharmaka GmbH and research grants from Ipsen and he is a member of Ipsen and Novartis speaker's bureau; UK has received research funding and speaker advisory board honoraria from Ipsen and Novartis; CLB has reported being an advisory board member for Novartis, Pfizer, Ipsen and AAA-Pharma; MP has reported being an advisory board member for and received honoraria from Novartis, Ipsen, Pfizer and Lexicon and has received research grants from Ipsen and Novartis; AB is a member of Novartis speaker's bureau; all other authors have declared no conflicts of interest.

PY - 2021/4/1

Y1 - 2021/4/1

KW - characterisation

KW - diagnosis

KW - lung carcinoids

KW - prognosis

KW - therapy

KW - thymic carcinoids

UR - http://www.scopus.com/inward/record.url?scp=85101051556&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.01.003

DO - 10.1016/j.annonc.2021.01.003

M3 - Article

C2 - 33482246

AN - SCOPUS:85101051556

SN - 0923-7534

VL - 32

SP - 439

EP - 451

JO - Annals of Oncology

JF - Annals of Oncology

IS - 4

ER -